Bordetella pertussis BPZE vaccine vector |
|
Vaxvec ID |
28 |
|
Vaccine Vector Name |
Bordetella pertussis BPZE vaccine vector |
|
Alternative Names |
B. pertussis BPZE |
|
Vector VO ID |
VO_0001037
|
|
Function |
Because B. pertussis is an infectious pathogen that colonizes the human respiratory tract, causing whooping cough, it is a good candidate to be a bacterial vaccine vector with the purpose of colonizing the respiratory tract but rather than infecting the host, inducing cellular and humoral immunity (Mielcarek et al., 2006). |
|
Advantage |
Because B. pertussis is so virulent (when it is not attenuated) it can induce strong mucosal and systemic humoral and cellular immune responses, as well as long-lasting protection. This ability to induce such strong immune responses means that it has the potential to be a suitable intranasal vaccine vector against many diseases with only one dose (Mielcarek et al., 2006). |
|
Disadvantage |
Because the B. pertussis toxin is so strongly virulent, a strain must be developed and well-proven to be attenuated before becoming safe for use (Mielcarek et al., 2006). |
|
Preparation |
In order to ensure attenuation of the toxin, allelic exchange is used to delete the dermonecrotic toxin gene and replace the pertussis toxin gene with an allele coding for inactivity of the toxin. The ampG gene is overexpressed in order to hinder the production of tracheal cytotoxin (Mielcarek et al., 2006). |
|
Safety |
The strains are well-attenuated by inactivating the pertussis toxin, so when inoculation occurs, the strains are no longer virulent and therefore safe (Mielcarek et al., 2006). |
|
Description |
Live, attenuated B. pertussis is a good candidate to be a vector for intranasal introduction of various diseases due to its ability to induce immune responses and quickly colonize the respiratory tract (Mielcarek et al., 2006). |
| Related Vaccine(s) |
|
| References |
Mielcarek et al., 2006: Mielcarek N, Debrie AS, Raze D, Quatannens J, Engle J, Goldman WE, Locht C. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation. Vaccine. 2006; 24 Suppl 2; S2-54-5. [PubMed: 16823926].
|
